PRIMA试验最终分析:尼拉帕利一线维持治疗患者报告结局及疾病进展对健康相关生活质量的影响
PRIMA/ENGOT-OV26/GOG-3012试验最终分析更新了患者报告结局,患者按2:1随机接受尼拉帕利或安慰剂一线维持治疗。尼拉帕利未对健康相关生活质量产生负面影响,早期胃肠道症状差异随时间消失;疾病进展导致各臂健康相关生活质量持续恶化且未恢复至进展前水平。
要点
- 尼拉帕利一线维持治疗与安慰剂相比未对健康相关生活质量产生负面影响。
- 疾病进展导致健康相关生活质量持续恶化,且未恢复至进展前水平。
- 延长无进展生存期对维持患者健康相关生活质量具有临床重要性。
核心结论
- 尼拉帕利一线维持治疗与安慰剂相比未对健康相关生活质量产生负面影响。
- 疾病进展导致各治疗臂健康相关生活质量持续恶化,强调延长无进展生存期以维持患者生活质量的临床重要性。
研究设计与样本
- PRIMA/ENGOT-OV26/GOG-3012试验最终分析,患者按2:1随机接受尼拉帕利一线维持治疗或安慰剂。
- 纵向健康相关生活质量为预设次要终点,采用EORTC QLQ-C30、EORTC QLQ-OV28、FOSI和EQ-5D-5L及EQ-VAS评估。
- 事后分析评估自基线或疾病进展前末次治疗访视的最小二乘均值变化,临床截止日期为2024年4月8日。
主要发现
- 问卷完成率在第24周期前超过89%,治疗结束时为80%。
- 两臂间胃肠道症状评分的早期差异随时间消退,总体健康相关生活质量未见差异。
- 疾病进展降低各臂总体健康相关生活质量,EORTC QLQ-C30总体健康相关生活质量、FOSI和EQ-VAS评分显著下降且从未恢复至进展前水平。
- 进展还导致所有EORTC QLQ-C30和QLQ-OV28功能量表持续恶化及症状评分加重,尤其是疲乏、呼吸困难、疼痛和食欲丧失。
- 按同源重组修复缺陷状态评估患者时观察到相似结果。
临床怎么用
- 尼拉帕利一线维持治疗期间应关注早期胃肠道症状,但总体健康相关生活质量与安慰剂相当。
- 疾病进展后需重视患者健康相关生活质量的持续恶化,尤其是疲乏、呼吸困难、疼痛和食欲丧失等症状。
- 临床决策中可将延长无进展生存期作为维持患者健康相关生活质量的重要目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report updated patient-reported (PRO) health-related quality of life (HRQOL) findings and evaluate the effect of disease progression on HRQOL using data from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial. METHODS: Patients were randomized 2:1 to niraparib first-line maintenance or placebo. Longitudinal HRQOL was a prespecified secondary endpoint assessed via European Organisation for Research and Treatment of Cancer QOL-Core Questionnaire (EORTC QLQ-C30) and -Ovarian Cancer module (EORTC QLQ-OV28), Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index (FOSI), and EuroQol 5-dimension 5-level questionnaire with visual analog scale (EQ-VAS). Post hoc analyses evaluated least-squares mean change from baseline or last on-treatment visit before disease progression (clinical cutoff: April 8, 2024). RESULTS: Questionnaire completion rates exceeded 89% through cycle 24 and were 80% at end of treatment. Early differences in gastrointestinal symptom scores between arms resolved over time, and no differences in overall HRQOL were observed. Disease progression reduced overall HRQOL across arms, with marked reductions in EORTC QLQ-C30 overall HRQOL, FOSI, and EQ-VAS scores that never recovered to pre-progression levels. Progression also resulted in sustained deterioration across all EORTC QLQ-C30 and QLQ-OV28 functional scales and worsening symptom scores, particularly for fatigue, dyspnea, pain, and appetite loss. Similar results were observed when patients were evaluated by homologous recombination deficiency status. CONCLUSION: In the final PRIMA PRO analysis, results confirmed that niraparib first-line maintenance did not negatively affect HRQOL versus placebo. Disease progression caused sustained HRQOL deterioration across arms, emphasizing the clinical importance of extending progression-free survival to preserve patient HRQOL. CLINICAL TRIAL REGISTRATION NUMBER: NCT02655016.
引用
- Shahin MS, Lorusso D, Backes FJ, et al. Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2026. PMID: 42385609. doi:10.1016/j.ygyno.2026.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。